Publications

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.

Pauli C, Puca L, Mosquera JMiguel, Robinson BD, Beltran H, Rubin MA, Rao RA.  2016.  An emerging role for cytopathology in precision oncology.. Cancer Cytopathol. 124(3):167-73.

Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA.  2016.  The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.. Eur Urol.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al..  2004.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.. Am J Pathol. 164(3):787-93.

Rubin MA, Allory Y, Molinié V, Leroy X, Faucon H, Vacherot F, Huang W, Kuten A, Salomon L, Rebillard X et al..  2005.  Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome.. Urology. 66(5):930-4.

Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Rodrigues DNava, Robinson D, Omlin A, Tunariu N et al..  2015.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.. N Engl J Med. 373(18):1697-708.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.  2016.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.. Eur Urol.

Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.

Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, Pflueger D, Pina C, Hofer MD, Sboner A et al..  2009.  Distinct genomic aberrations associated with ERG rearranged prostate cancer.. Genes Chromosomes Cancer. 48(4):366-80.

Pflueger D, Terry S, Sboner A, Habegger L, Esgueva R, Lin P-C, Svensson MA, Kitabayashi N, Moss BJ, MacDonald TY et al..  2011.  Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.. Genome Res. 21(1):56-67.

Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R.  2008.  Detection of early prostate cancer using a hepsin-targeted imaging agent.. Cancer Res. 68(7):2286-91.

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.

Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami H-O et al..  2005.  Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.. Cancer Epidemiol Biomarkers Prev. 14(6):1424-32.

Setlur SR, Rubin MA.  2005.  Current thoughts on the role of the androgen receptor and prostate cancer progression.. Adv Anat Pathol. 12(5):265-70.

Mosquera JMiguel, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir, iv R et al..  2013.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.. Neoplasia. 15(1):1-10.

Gayvert KM, Dardenne E, Cheung C, Boland MRegina, Lorberbaum T, Wanjala J, Chen Y, Rubin MA, Tatonetti NP, Rickman DS et al..  2016.  A Computational Drug Repositioning Approach for Targeting Oncogenic Transcription Factors.. Cell Rep. 15(11):2348-56.

Rubin MA, Maher CA, Chinnaiyan AM.  2011.  Common gene rearrangements in prostate cancer.. J Clin Oncol. 29(27):3659-68.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, rosenberg jonathan, Mosquera JMiguel, Robinson B, Elemento O et al..  2016.  Clonal evolution of chemotherapy-resistant urothelial carcinoma.. Nat Genet. 48(12):1490-1499.

Fontugne J, Davis K, Palanisamy N, Udager A, Mehra R, McDaniel AS, Siddiqui J, Rubin MA, Mosquera JMiguel, Tomlins SA.  2016.  Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry.. Mod Pathol. 29(2):157-65.

Feng FY, de Bono JS, Rubin MA, Knudsen KE.  2015.  Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.. Mol Cell. 58(6):925-34.

Mosquera J-M, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G et al..  2008.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.. Clin Cancer Res. 14(11):3380-5.

D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JMiguel, MacDonald TY, Noorzad Z, Orta LY, Liu Y-F, Rubin MA, Shin SJ.  2016.  Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast.. Hum Pathol.

Rubin MA, Chinnaiyan AM.  2006.  Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.. Lab Invest. 86(11):1099-102.